Fig. 1 · Structure

Documents & Downloads

Dexrazoxane HCl

Cat. No. A10300 CAS 149003-01-0
Dexrazoxane hydrochloride is a cardioprotective agent. As a derivative of EDTA, dexrazoxane chelates iron, but the precise mechanism by which it protects the heart is not known. This agent is used to protect the heart against the cardiotoxic side effects of anthracyclines, such as doxorubicin.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Dexrazoxane (ICRF-187) is associated with reduced topoisomerase IIβ protein levels and reduced doxorubicin-induced DNA-damage signalling in differentiated H9C2 cells. The non-depleting analogue ICRF-161 did not reproduce these effects. These findings support a role for topoisomerase II biology in protection; they do not establish a single exclusive cardioprotective mechanism. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Dexrazoxane HCl Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of Dexrazoxane HCl from 3 published references. In vitro models include differentiated rat H9C2 cardiomyoblast-derived cells; human HL-60 promyelocytic leukemia cell line. In vivo models include wild-type C57BL/6J mice, 8–12 weeks old.

Dexrazoxane HCl In Vitro Studies

In primary neonatal rat ventricular cardiomyocytes, dexrazoxane pretreatment reduced anthracycline-induced LDH release at responsive concentrations but did not significantly protect against hydrogen-peroxide injury. The response was not consistently dose-dependent. The tested dexrazoxane salt form was not specified. [2]

Dexrazoxane inhibited HL-60 proliferation with a reported 72-h IC50 of 25 μM. Anthracycline combinations were generally synergistic, but pre-incubation before daunorubicin weakened synergy and yielded additive or moderately antagonistic interactions at the highest equipotent concentrations. Anticancer compatibility therefore depends on the model, concentration ratio and schedule. [2]

Top2b depletion and doxorubicin-associated DNA-damage signalling in differentiated H9C2 cells

Cell-based study · Differentiated rat H9C2 cardiomyoblast-derived cells [1]

Dexrazoxane depleted Top2b and reduced doxorubicin-induced γ-H2AX accumulation. ICRF-161 did neither; ICRF-193 depleted Top2b. These are protein/signalling endpoints and support an association with topoisomerase II biology, rather than a direct cardiac-function measurement.

Literature-Reported Treatment Conditions

Treatment concentration
100 μM dexrazoxane; 1 μM doxorubicin for the DNA-damage comparison
Exposure duration
24 h
Method
Cell treatment; Western blots for Top2 isoforms and γ-H2AX with tubulin loading controls
Co-treatment
Doxorubicin co-treatment in Figure 2D; analogues are separate comparators
Reported limits
Vehicle not specified for this cellular experiment. No numerical depletion percentage or IC50 is extracted.
Methods and source locations

Compound reported in the paper: Dexrazoxane; Compound label in the paper: DRZ (ICRF-187)

Dexrazoxane active-compound evidence only. The tested preparation is not verified as A10300 hydrochloride or an Adooq lot; retain the paper’s units without salt conversion.

Figure 2B–D; Results: DRZ depletes cardiac TOP2B protein both in vitro and vivo; Methods: Drugs and antibodies, Cell culture, Western blot

Anthracycline versus hydrogen-peroxide injury in primary cardiomyocytes

Cell-based study · Primary neonatal ventricular cardiomyocytes isolated from 2-day-old Wistar rats [2]

Dexrazoxane pretreatment reduced anthracycline-induced LDH release at responsive concentrations, but showed no significant protection from hydrogen-peroxide injury. Protection was not consistently greater at 1000 μM than at lower dexrazoxane concentrations.

Literature-Reported Treatment Conditions

Treatment concentration
Dexrazoxane 10, 100 or 1000 μM; daunorubicin or doxorubicin 0.6–2.0 μM; H2O2 200, 300 or 500 μM
Exposure duration
Dexrazoxane pretreatment 3 h; anthracycline co-incubation 3 h followed by 48 h anthracycline-free period; H2O2 comparison 48 h
Method
LDH release expressed as percentage of total cellular LDH
Vehicle
DMSO; drug-free DMSO control
Co-treatment
Separate daunorubicin, doxorubicin or H2O2 injury comparisons
Reported limits
No exact bar-height values or IC50 inferred; final DMSO percentage not specified in the read methods.
Methods and source locations

Compound reported in the paper: Dexrazoxane; Compound label in the paper: DEX (ICRF-187)

Dexrazoxane active-compound evidence only. The tested preparation is not verified as A10300 hydrochloride or an Adooq lot; retain the paper’s units without salt conversion.

Figure 2A–C and caption; Methods 1–2, 8; Results 1

Schedule-dependent interactions with anthracyclines in HL-60 cells

Cell-based study · Human HL-60 promyelocytic leukemia cell line [2]

Dexrazoxane had a reported 72-h antiproliferative IC50 of 25 μM. Simultaneous combinations with daunorubicin or doxorubicin were generally synergistic. Dexrazoxane pre-incubation before daunorubicin weakened synergy, with additive or moderately antagonistic behaviour at the highest equipotent concentrations. These observations do not establish preservation of anticancer efficacy in other models.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% proliferation decrease relative to untreated cells after single-agent dexrazoxane exposureIC50 25 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Single-agent IC50 reported as 25 μM; combination series at 1/8, 1/4, 1/2, 1, 2 and 4 times individual IC50 values, and separate 1:20 daunorubicin:dexrazoxane ratio
Exposure duration
72-h co-incubation; additional dexrazoxane pre-incubation for 3 or 6 h; fixed-ratio comparison with 0 or 3 h pre-incubation
Method
MTT assay; Chou–Talalay combination analysis and simulated fraction-affected/combination-index curves
Vehicle
DMSO
Co-treatment
Daunorubicin or doxorubicin; qualitative interactions only
Reported limits
Table S1 not retrieved as usable original table; exact CI values, their variability and pair-specific values are not extracted. Figure 4 curves are simulations, not raw observations.
Methods and source locations

Compound reported in the paper: Dexrazoxane; Compound label in the paper: DEX (ICRF-187)

Dexrazoxane active-compound evidence only. The tested preparation is not verified as A10300 hydrochloride or an Adooq lot; retain the paper’s units without salt conversion.

Methods 1, 3, 8; Results 2; Figure 4A and caption; Discussion combination-schedule paragraph

50% proliferation decrease relative to untreated cells after single-agent dexrazoxane exposure: 72-h MTT proliferation assay; CalcuSyn median-effect analysis — Results 2: Proliferation studies, first paragraph; Methods 3 and 8

Dexrazoxane HCl In Vivo Studies

A single 200 mg/kg intraperitoneal dexrazoxane dose reduced cardiac Top2b protein in C57BL/6J mice, with partial recovery by 48 h. This experiment measured protein expression; it did not establish cardiac functional protection or reduced DNA damage in vivo. [1]

In male rabbits receiving weekly daunorubicin for 10 weeks, Cardioxane dexrazoxane co-treatment preserved LV systolic function and reduced myocardial TUNEL positivity and caspase activation. Protection occurred without a significant reduction in myocardial malondialdehyde versus daunorubicin alone. This was a combination-treatment experiment using a pharmaceutical preparation, not an Adooq lot. [3]

Transient cardiac Top2b depletion after dexrazoxane in mice

Animal study · Wild-type C57BL/6J mice, 8–12 weeks old [1]

Cardiac Top2b protein was reduced after dexrazoxane and partially recovered by 48 h. This acute pharmacodynamic study did not demonstrate reduced cardiac DNA damage or improved heart function.

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single injection
Treatment course
6, 24 and 48 h sampling
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dexrazoxane time-course comparison
200 mg/kg dexrazoxane
100 μl saline, n=3; dexrazoxane n=9 total across sampling timesReduced cardiac Top2b expression with partial recovery by 48 h; qualitative direction only.[1]
Dexrazoxane time-course comparison
Model: C57BL/6J mice, 8–12 weeks
Reported limits: Sex and allocation per sampling time not specified in Mice and treatment.
Methods and source locations

Compound reported in the paper: Dexrazoxane; Compound label in the paper: DRZ (ICRF-187)

Dexrazoxane active-compound evidence only. The tested preparation is not verified as A10300 hydrochloride or an Adooq lot; retain the paper’s units without salt conversion.

Figure 1A,C; Methods: Mice and treatment, Western blot; Results first paragraph; Discussion in-vivo DSB limitation

Dexrazoxane time-course comparison · Figure 1A; Methods: Mice and treatment

Chronic daunorubicin cardiotoxicity and dexrazoxane co-treatment in rabbits

Animal study · Male Chinchilla rabbits; saline n=8, daunorubicin n=11, dexrazoxane plus daunorubicin n=8 at randomization [3]

Dexrazoxane co-treatment preserved LV systolic function and reduced myocardial TUNEL positivity and caspase activation compared with daunorubicin alone. Two of eleven daunorubicin-only animals died prematurely; all eight combination-treated animals survived. Myocardial MDA remained significantly elevated relative to saline and was not significantly reduced versus daunorubicin alone.

Conditions shared by the study groups

Route
Dexrazoxane intraperitoneal; daunorubicin intravenous
Frequency
Once weekly; dexrazoxane 30 min before each daunorubicin administration
Treatment course
10 weeks; terminal assessments 5–7 days after last administration
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dexrazoxane before daunorubicin
Dexrazoxane 60 mg/kg plus daunorubicin 3 mg/kg
Daunorubicin alone (n=11 at randomization) and intravenous saline 1 ml/kg (n=8); no dexrazoxane-alone groupPreserved LV function, lower TUNEL/caspase readouts; MDA not significantly reduced versus daunorubicin alone. All eight combination animals survived; two of eleven daunorubicin-only animals died prematurely.[3]
Dexrazoxane before daunorubicin
Model: Male Chinchilla rabbits; combination group n=8 at randomization
Reported limits: Dexrazoxane reconstitution vehicle not specified; individual terminal endpoint denominators not assumed from initial group sizes.
Methods and source locations

Compound reported in the paper: Dexrazoxane; Compound label in the paper: DEX (Cardioxane; ICRF-187)

Dexrazoxane active-compound evidence only. The tested preparation is not verified as A10300 hydrochloride or an Adooq lot; retain the paper’s units without salt conversion.

Methods: Animals and study design, Cardiac function measurements, TUNEL/caspase/lipoperoxidation methods, Data analysis; Results: General toxicity, LV function, TUNEL, Caspase activity, Myocardial lipoperoxidation; Figures 1, 4, 5, 7

Dexrazoxane before daunorubicin · Animals and study design; General toxicity; Figures 1,4,5,7 and captions

Specifications

Manufacturer Adooq Bioscience
CAS Number 149003-01-0
Formula C11H17ClN4O4
Molecular Weight 304.7
Synonyms Totect; ICRF-187; Zinecard; Cardioxane
SMILES
C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 55 mg/mL (180.48 mM)
Water Warmed: 55 mg/mL (180.48 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Dexrazoxane HCl Research References

  1. [1] Shiwei Deng, Tiandong Yan, Cathleen Jendrny, et al. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms BMC Cancer (2014). PMID: 25406834 DOI: 10.1186/1471-2407-14-842 Source material
  2. [2] Anna Vavrova, Hana Jansova, Eliska Mackova, et al. Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells PLoS ONE (2013). PMID: 24116135 DOI: 10.1371/journal.pone.0076676 Source material
  3. [3] O Popelová, M Štěrba, P Hašková, et al. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death British Journal of Cancer (2009). PMID: 19623174 DOI: 10.1038/sj.bjc.6605192 Source material

Added to your cart

View Cart Checkout
Loading...